Thu, Jan 25, 2024
The company had posted a profit of Rs 109.7 crore in the third quarter of last fiscal, Syngene International said in a regulatory filing. Consolidated revenue from operations during the quarter under review stood at Rs 853.5 crore as against Rs 785.9 crore in the year-ago period, it added.
More >
Wed, Oct 18, 2023
CorporateRadar, Demand trend of large pharma strong, Demand trend of small pharma will improve in 1-2 quarters. Acquired Stelis Biopharma last quarter, Mahesh Bhalgat. Watch Swati Khandewal's exclusive conversation with Mahesh Bhalgat, COO of Syngene International.
Thu, Jul 27, 2023
Due to strong demand, expect good performance in future, will spend funds on new acquisitions, capacity expansion: Dr. Mahesh Bhalgat, COO, Syngene International
Wed, Jul 26, 2023
Contract manufacturing services firm Syngene International on Wednesday said its consolidated net profit increased 26 per cent to Rs 93 crore in the June quarter.
Thu, Apr 27, 2023
Syngene International, the listed contract research and manufacturing services arm of Biocon reported a 21% year-on-year (YoY) jump in net profit to Rs.179 crore in Q4FY23. What were the reasons for the margin pressure? What were the key triggers for the results? Watch Anil Singhvi's exclusive interview with Dr. Mahesh Bhalgat, COO of Syngene International.
Tue, Jan 24, 2023
Syngene profit up 6%, income up 23% in December quarter. Margin under pressure in Q3. Watch an exclusive interview with Dr. Mahesh Bhalgat, COO, Syngene International on the results.
Thu, Oct 20, 2022
Good demand across all segments: Mahesh Bhalgat, COO, Syngene International. Watch Anil Singhvi's exclusive conversation with Syngene International, COO, Mahesh Bhalgat on September results.
Thu, Sep 08, 2022
Stocks to buy today: In a special segment ‘Bhasin Ke Hasin Share' aired on Zee Business with Managing Editor Anil Singhvi, Sanjiv Bhasin picked two stocks for investors - Escorts Kubota and Syngene International.
Thu, Apr 28, 2022
Syngene International COO, Dr Mahesh Bhalgat had an exclusive conversation with Zee Business Executive Editor Swati Khandelwal on March quarter results. In a conversation, he says, "The performance of all the four divisions in Q4 was strong. Profit down 8.1% in Q4 to ₹148 Cr. Expecting good performance in biologics in future as well. Margins stood at 33% in March quarter." What are the key triggers for the results? What is the growth outlook for the future? Watch this video to know more.
Thu, Jan 20, 2022
Indian market closed lower on Thursday for the third consecutive day in a row.
Thu, Oct 21, 2021
During the quarter, the company said it has taken an exceptional downward adjustment of Rs 25.3 crore (net of tax) on account of the government's recent decision in the quarter to cap the Services Export Incentive Scheme (SEIS) for research and development services at Rs 5 crore for the financial year 2020
Fri, Oct 02, 2020
Contract research and manufacturing services company Syngene International Ltd. said on Friday that it has joined a global consortium of 19 organisations from the healthcare industry to help accelerate various aspects of Covid-19 testing.
Tue, Nov 14, 2017
Biocon's contract research arm Syngene International has expanded its ongoing drug discovery and development with US-based Bristol-Myers Squibb till 2026.
Tue, Dec 13, 2016
It said, "Syngene is in the process of assessing the extent of damage to the building and equipment and also implementating a business continuity plan to minimize impact on operations."
By accepting cookies, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts.
